A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer - Contacts and Locations

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.

Study NCT00544960. Last updated on August 14, 2008. Information provided by Ascenta Therapeutics

Please refer to this study by its ClinicalTrials.gov identifier: NCT00544960

Locations


United States, North Carolina
	Research Site
	Durham, North Carolina, United States

Russian Federation
	Research Site
	Arkhangelsk, Russian Federation
	Research Site
	Chelyabinsk, Russian Federation
	Research Site
	Ekaterinburg, Russian Federation
	Research Site
	Samara, Russian Federation
	Research Site
	Kazan, Russian Federation
	Research Site
	Moscow, Russian Federation
	Research Sites (4)
	Saint Petersburg, Russian Federation
	Research Site
	Kaliningrad, Russian Federation
	Research Site
	Stavropol, Russian Federation
	Research Site
	Voronezh, Russian Federation

Ukraine
	Research Site
	Dnipropetrovsk, Ukraine
	Research Site
	Donetsk, Ukraine
	Research Site
	Lugansk, Ukraine
	Research Site
	Zaporizhzhya, Ukraine
	Research Site
	Kharkiv, Ukraine
	Research Site
	Uzhgorod, Ukraine
	Research Site
	Kyiv, Ukraine

Sponsors and Collaborators

Ascenta Therapeutics

Investigators


Study Chair:	Lance Leopold, MD	Ascenta Therapeutics, Inc.